SCHEMBL23540576

SCHEMBL23540576

COC(=O)c1cc(I)c(-c2cc(Cl)c(F)cc2F)cc1NC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.41
▸ ACLY P53396 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ HPGD P15428 3/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ KDM4E B2RXH2 4/20 0.36
▸ ALPL P05186 1/20 0.36
▸ NQO2 P16083 1/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CASP3 P42574 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ CFTR P13569 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29476351 1.00 ALDH1A1 (0.41) ALDH1A1ACLYSMN1; SMN2HPGDNPC1
SCHEMBL25485799 0.87 ALDH1A1 (0.42) ALDH1A1ACLYSMN1; SMN2HPGDNPC1
SCHEMBL25486721 0.85 ABL1 (0.44) ALDH1A1ACLYSMN1; SMN2HPGDNPC1
SCHEMBL29654773 0.85 ABL1 (0.44) ALDH1A1ACLYSMN1; SMN2HPGDNPC1
SCHEMBL23539849 0.84 ALDH1A1 (0.40) ALDH1A1ACLYHPGDNPC1RAB9A
SCHEMBL29476206 0.84 ALDH1A1 (0.40) ALDH1A1ACLYHPGDNPC1RAB9A
SCHEMBL23539577 0.82 ALPL (0.43) ALDH1A1SMN1; SMN2HPGDNPC1RAB9A
SCHEMBL29476340 0.81 CFTR (0.51) ALDH1A1ACLYHPGDKDM4EALPL
SCHEMBL23540452 0.81 CFTR (0.51) ALDH1A1ACLYHPGDKDM4EALPL
SCHEMBL7761264 0.79 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2HPGDKDM4ENQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217071-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES Erasca, Inc. (US) 2023-08-02 — — EP disclosed
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-06-29 — — US disclosed
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-06-29 — — US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 — — US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 — — US disclosed
WO-2022133345-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2022-06-23 — — WO disclosed
WO-2022133345-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2022-06-23 — — WO disclosed
US-20220119409-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2022-04-21 — — US disclosed
WO-2021127404-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2021-06-24 — — WO disclosed
WO-2021127404-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES TYMS, TYMP, DHFR ALDH1A1 547/4885ACLY 4156/4885SMN1; SMN2 1154/4885
US-20220119409-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES DHFR, TYMS, TYMP ALDH1A1 564/4885ACLY 4123/4885SMN1; SMN2 1205/4885
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES KRAS, NRAS, HRAS ALDH1A1 2548/4885ACLY 4774/4885SMN1; SMN2 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback